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Purpose: Although expert guidelines for the treatment of schizophrenia recommend 
antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study 
identified characteristics that differentiate patients with schizophrenia who are treated with 
olanzapine monotherapy versus polypharmacy in usual care in Japan.
Patients and methods: In a large (N = 1850) prospective, observational study, Japanese 
patients with schizophrenia who initiated treatment with olanzapine were followed for 1 year. 
Consistent with past research, antipsychotic polypharmacy was defined as the concurrent use of 
olanzapine and another antipsychotic for at least 60 days. Switching was defined as discontinuing 
a prior antipsychotic therapy rather than augmenting the medication regimen. Predictors of 
antipsychotic monotherapy were based on information available at the time of olanzapine 
initiation. Baseline characteristics were compared using t-tests and χ2 tests. Stepwise logistic 
regression was used to identify independent predictors of monotherapy.
Results: Patients treated with olanzapine monotherapy (43.2%) differed from those treated with 
antipsychotic polypharmacy (56.8%) on demographics, treatment history, baseline symptom 
levels, functional levels, and treatment-emergent adverse events. Stepwise logistic   regression 
identified multiple variables that significantly predicted monotherapy: older age, shorter 
  duration of schizophrenia, outpatient status, comorbid medical conditions, lower body mass 
index, no prior anticholinergic use, no prior mood stabilizer use, and switching from a previous 
antipsychotic (typical or atypical).
Conclusion: Consistent with prior research in Japan, antipsychotic polypharmacy appears 
to be common in the treatment of schizophrenia. Patients treated with monotherapy could be 
differentiated from those treated with antipsychotic polypharmacy based on a specific set of 
demographic and baseline clinical characteristics.
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Introduction
Treatment guidelines consider antipsychotic medications to be the cornerstone of 
treatment in schizophrenia.1,2 Antipsychotic monotherapy is recommended over 
antipsychotic polypharmacy, which is defined as the concurrent use of two or 
more antipsychotic drugs.2 Despite the consistent preference for monotherapy,1–3 
polypharmacy is frequently used in the treatment of schizophrenia,4–7 and its use 
appears to be increasing over time.5,7
Antipsychotic polypharmacy is initiated for a variety of reasons, but most are related 
to the need for further control of the positive or negative symptoms of schizophrenia.8,9 
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empirical evidence does not support the observed prevalence 
of antipsychotic polypharmacy.3,10 Although the supporting 
evidence is limited, the drawbacks are clear: polypharmacy 
increases the risk of drug–drug interactions,11,12 treatment-
emergent adverse events,13 antipsychotic costs,7 and treatment 
regimen complexity.11 Treatment regimens with multiple 
antipsychotics are more difficult to evaluate and modify when 
needed, because the effects of each antipsychotic cannot be 
easily disentangled.11
Estimates of the prevalence of antipsychotic poly-
pharmacy in schizophrenia have ranged widely from 13% 
to 70%.5,7,9,14–18 The wide range appears to result from 
differences in study design characteristics, including patient 
population, treatment characteristics, and the specific 
country studied. Patient population factors associated with 
higher polypharmacy include demographic characteristics 
such as younger age18,19 and male gender,5 more frequent 
concomitant psychotropic medication use,5,6,15,18 and clinical 
characteristics such as inpatient treatment setting5 and greater 
symptom severity.6 In addition, polypharmacy appears to 
vary by antipsychotic treatment, with olanzapine-treated 
patients being more likely to be treated with monotherapy 
than patients treated with quetiapine,4,20–22 risperidone,4,22,23 or 
typical antipsychotics.23 In Japan, the rate of polypharmacy 
appears to be particularly prevalent, with estimates ranging 
between 46.7% and 69.3%.24,25
Due to the high prevalence of antipsychotic polypharmacy 
in schizophrenia and the potential problems   associated with its 
use, research is needed to better understand this   phenomenon 
and help identify the characteristics differentiating 
  monotherapy-treated patients from   polypharmacy-treated 
patients. The objective of this study was to identify demo-
graphic and baseline clinical characteristics that differentiate 
patients with schizophrenia who are treated with olanzapine 
monotherapy versus olanzapine polypharmacy over a 1-year 
period in usual care in Japan.
Methods
Data source
The data for this research came from the Olanzapine Post 
Marketing Surveillance (OPMS) study. The OPMS study 
is a large multicenter, naturalistic, 1-year study in Japan 
with 1850 participants meeting the inclusion criteria. The 
inclusion criteria included having a schizophrenia diagnosis 
based on the Diagnostic and Statistical Manual of the 
American Psychiatric Association, Fourth Edition, as well 
as being initiated with olanzapine treatment. This naturalistic 
study was designed to be minimally invasive in usual care; 
all of the treatment decisions were left to the treating phy-
sician. Enrollment for the study began in November 2003 
and finished in July 2004. The follow-up period continued 
for 1 year after enrollment or until the patient discontinued 
treatment with olanzapine. Data were collected at the base-
line, 3-month, 6-month, and 12-month visits. The internal 
review boards at each of the participating institutions 
approved the study procedures, and informed consent was 
obtained based on the rules set at these facilities.
Measures and definitions
A number of clinical variables were assessed at baseline and 
used to help differentiate patients who were treated with 
olanzapine monotherapy versus polypharmacy. The Clinical 
Global Impression-Schizophrenia (CGI-SCH) scale was 
used to measure the symptom severity level. The ratings are 
made on an anchored scale ranging from no symptoms (0) to 
severe symptoms (6).26 Assessment of the concurrent validity 
of the CGI-SCH scale and the more rigorous Positive and 
Negative Syndrome Scale27 found the validity coefficients to 
range from 0.61 for depressive symptoms to 0.86 for positive 
symptoms with the remaining coefficients ranging from 0.75 
to 0.80. Moderately high inter-rater reliability has also been 
reported (interclass correlation coefficients ranging from 0.73 
to 0.82) for all but the depressive subscale (0.64).26
Health-related quality of life was measured using the 
European Quality of Life 5-Dimensions visual analog scale 
(EQ-5D VAS). The EQ-5D VAS, on this generic measure of 
health-related quality of life, ranges from 0 to 100.
In addition to these published scales and demographic 
information, several other baseline characteristics were used 
to predict later antipsychotic monotherapy use. Outpatient 
(versus inpatient) status was defined based on the patients’ 
treatment setting at the baseline visit. Prior medication 
use was assessed using indicator variables for prior use 
of antipsychotics, anticholinergics, anxiolytics/hypnotics, 
mood stabilizers, antidepressants, or other medications. 
An indicator variable for existing medical comorbidities 
was coded if any of the following medical conditions were 
present at baseline: hypertension, hyperlipidemia, hepatic 
dysfunction, renal dysfunction, or other. Social activity was 
coded if patients reported one or more social activities in 
the 4 weeks prior to baseline. Work status and living status 
were defined based on the patients’ status during the 4 weeks 
prior to baseline. Switching from a typical antipsychotic 
was coded if the patient discontinued a typical antipsychotic 
prior to initiating olanzapine. Similarly, switching from an 
atypical antipsychotic was coded if the patient discontinued ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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an atypical antipsychotic prior to the initiation of olanzapine. 
The patients who did not switch antipsychotics to olanzapine 
either initiated antipsychotic therapy with olanzapine or 
augmented their previous antipsychotic treatment regimen 
with olanzapine.
Consistent with past research, antipsychotic polyphar-
macy was defined as using one or more antipsychotics in 
conjunction with olanzapine for a period of at least 60 con-
secutive days.4 Conversely, antipsychotic monotherapy was 
defined as the use of olanzapine as the primary antipsychotic 
during the 1-year study.
statistical methods
The differences between the baseline characteristics of 
patients treated with either monotherapy or polypharmacy 
were examined using χ2 tests for categorical variables and 
t-tests for continuous variables. Stepwise logistic regres-
sion was used to identify independent predictors of later 
monotherapy use. Table 1 provides a list of the baseline pre-
dictors used in the stepwise logistic regression. A t-test was 
used to compare early (3-month) change in CGI-SCH global 
severity between monotherapy- and polypharmacy-treated 
patients, with missing values imputed using the last observa-
tion carried forward approach. The level of significance was 
set at α = 0.05, and all analyses were computed using SAS 
(v 9.1.3; SAS Institute Inc, Cary, NC).
Results
sample description
The OPMS study registered and enrolled 1949 patients, of 
whom 1850 (94.9%) met all of the entry criteria for the study. 
Participants who were excluded from the study included 27 
who were in violation of the contract or registration, 20 who 
had no case report form, 49 who did not return after the initial 
visit, and three who did not initiate treatment with olanzapine. 
For the entire sample, the average age was 44.8 ± 15.5 years, 
Table 1 Baseline characteristics of patients on monotherapy and polypharmacy
Characteristic Total (N) Monotherapy 
(N = 800)
Polypharmacy 
(N = 1050)
P
Demographics
Age (y), mean ± sD 1850 42.1 ± 16.2 46.8 ± 14.6 ,0.001
Female (%) 1850 51.1 43.5 0.001
Clinical status
Outpatient status (%) 1850 53.1 35.7 ,0.001
Duration of illness (y), mean ± sD 1451 14.0 ± 14.5 21.3 ± 14.2 ,0.001
Tardive dyskinesia (%) 1822 7.0 6.8 0.88
BMi (kg/m2), mean ± sD 1638 22.0 ± 3.9 23.0 ± 4.1 ,0.001
Any medical comorbidities (%) 1849 28.7 42.0 ,0.001
Clinical and functional measures
Cgi-sCh global severity, mean ± sD 1822 3.3 ± 1.0 3.4 ± 1.1 ,0.001
EQ-5D VAs, mean ± sD 1815 45.1 ± 22.7 49.6 ± 22.2 ,0.001
social activities (%) 1820 31.0 26.9 0.085
Working for pay (%)a 1820 13.0 5.9 ,0.001
  Outpatients only (%)b 785 21.0 14.3 0.015
  inpatients only (%)b 1035 4.1 1.2 0.003
Living independently (%)a 1822 21.7 13.8 ,0.001
  Outpatients only (%)b 786 32.7 31.9 0.81
  inpatients only (%)b 1036 9.3 3.7 ,0.001
Baseline and prior medication use
starting dose of OLZ (mg/day), mean ± sD 1847 8.5 ± 5.3 8.6 ± 5.0 0.83
switch from atypical antipsychotic (%) 1850 31.1 13.0 ,0.001
switch from typical antipsychotic (%) 1850 17.3 12.6 0.005
Prior anticholinergic use (%) 1823 23.6 52.2 ,0.001
Prior antidepressant use (%) 1823 6.8 4.4 0.030
Prior anxiolytic/hypnotic use (%) 1823 55.6 62.6 0.003
Prior mood stabilizer use (%) 1823 8.0 16.7 ,0.001
Prior other medication use (%) 1823 27.8 50.7 ,0.001
Notes: aThe working for pay status and living independently status refer to the 4 weeks prior to initiating olanzapine; bthe inpatient and outpatient status refers to the 
treatment setting when olanzapine was initiated. 
Abbreviations: BMi, body mass index; Cgi-sCh, Clinical global impression-schizophrenia; EQ-5D, European Quality of Life 5-Dimensions; OLZ, olanzapine; sD, standard 
deviation; y, year; VAs, visual analog scale.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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984 were male (53.2%), 43.2% were outpatients, and the 
mean duration of illness was 18.3 ± 14.7 years.
Table 1 displays the baseline characteristics for patients 
who were treated with olanzapine monotherapy (43.2%) or 
antipsychotic polypharmacy (56.8%). There were significant 
differences between these two groups on various demograph-
ics (age and gender), baseline clinical status (outpatient treat-
ment, duration of illness, body mass index [BMI], medical 
comorbidities), baseline clinical and functional measures 
(CGI-SCH global severity, EQ-5D VAS, working for pay, 
living independently), and prior medication use (switch from 
a typical or an atypical antipsychotic, anticholinergic use, 
antidepressant use, anxiolytic use, mood stabilizer use, and 
other medication use). Only the rates of tardive dyskinesia, 
level of social activities, and starting dose of olanzapine 
did not significantly differ between the two groups. Table 2 
displays the commonly used concomitant antipsychotics and 
the average doses among the 1050 antipsychotic polyphar-
macy patients.
In the stepwise logistic regression analysis, fewer vari-
ables independently differentiated patients who were treated 
with antipsychotic monotherapy or polypharmacy. Figure 1 
presents the odds ratios and confidence intervals for the final 
stepwise logistic regression model. The model was reasonably 
accurate in identifying patients who were treated with 
olanzapine monotherapy. The c-statistic of 0.765 indicated that 
the model could accurately classify a randomly selected indi-
vidual who was administered monotherapy and a randomly 
selected individual who was administered polypharmacy   
76.5% of the time. For the continuous predictor variables in 
the model (age, duration of illness, and BMI), the odds ratios 
represent the change in odds of monotherapy for every one-
unit increase in the predictor. For example, the significant odds 
ratio of 1.03 for age indicates that for every year older a patient 
was, the odds the patient would be treated with monotherapy 
were 1.03 times higher.
Early change (from baseline to the 3-month visit, the 
earliest postbaseline visit) in the CGI-SCH global severity 
was compared between the monotherapy- and polypharmacy-
treated patients. Monotherapy patients experienced 
significantly larger improvements in CGI-SCH global 
severity (−0.73) compared with patients who were treated 
with polypharmacy (−0.57; P , 0.001).
Discussion
In this large prospective, observational study, Japanese 
patients with schizophrenia who were treated with olanzapine 
monotherapy were found to significantly differ from those 
treated with polypharmacy on demographics, clinical status 
variables, baseline symptom and functional levels, and prior 
medication use. In the univariate analyses, nearly all of the 
baseline predictors were found to be significant. However, 
fewer of these baseline patient characteristics independently 
predicted later olanzapine monotherapy use from antipsy-
chotic polypharmacy use in the multivariate analysis. In the 
multivariate stepwise logistic regression model, antipsychotic 
monotherapy with olanzapine was significantly predicted by 
older age, outpatient status, switching from typical antip-
sychotics, switching from atypical antipsychotics, shorter 
illness duration, lower BMI, no prior medical comorbidities, 
no prior mood stabilizer use, and no prior anticholinergic use. 
In general, the patients receiving antipsychotic monotherapy 
appeared to have a somewhat simpler clinical profile.
Past research corroborated most, but not all, of these 
predictors of antipsychotic monotherapy. Studies from other 
geographies found that antipsychotic monotherapy use was 
predicted by older age,18,19 shorter duration of illness,18 outpa-
tient treatment or no prior psychiatric inpatient treatment,5,19 
no concomitant anticholinergic use,18,19 and no concomitant 
mood stabilizer use.5,19 A study of Veterans Affairs schizo-
phrenia patients in the US19 found that medical comorbidities 
Table 2 Concomitant antipsychotic medications used in poly-
pharmacya
Antipsychotic N Percent Mean dose
Atypical antipsychotics 632 60.2 nAb
Risperidone 420 40.0 5.5
Quetiapine 156 14.9 341.8
Zotepine 128 12.2 149.4
Perospirone 103 9.8 29.5
Typical antipsychotics 814 77.5 nAb
Levomepromazine 358 34.1 77.2
haloperidol 316 30.1 10.5
Chlorpromazine 221 21.0 159.3
Bromperidol 93 8.9 13.1
sulpiride 78 7.4 317.8
Chlorpromazine/promethazine 55 5.2 nAb
sultopride 49 4.7 706.9
Propericiazine 46 4.4 53.3
Chlorpromazine/phenobarbital/ 
promethazine
38 3.6 nAb
Timiperone 24 2.3 14.7
Perphenazine 21 2.0 13.7
Other typical use 82 7.8 nAb
Other antipsychotics 59 5.6 nAb
Notes:  asome patients used multiple concomitant antipsychotics; therefore, the 
percentages add up to more than 100. Concomitant use was defined as one or more 
days of use in conjunction with olanzapine. All doses are in milligrams per day; bnA 
indicates not applicable and was used for combination products or groups containing 
multiple antipsychotics.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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predicted lower use of antipsychotic polypharmacy, which 
is the opposite direction of the results found in this current 
research study. It is unclear whether this discrepancy is a 
function of different populations (the Veterans Affairs sample 
is almost all older males), study methods, or the restriction 
to olanzapine treatment in the current study.
A unique finding in this study was that switching from 
either typical or atypical antipsychotics to olanzapine was 
highly predictive of olanzapine monotherapy. By definition, 
switching antipsychotics limits polypharmacy because the 
original antipsychotic is discontinued instead of having an 
additional antipsychotic added to it. Similarly to past research 
outside of Japan, certain patients with schizophrenia had a 
substantially higher propensity for being treated with antip-
sychotic monotherapy.
Consistent with the notion that antipsychotic polyp-
harmacy arises as a result of poor or suboptimal treatment 
response, this study found greater 3-month symptom improve-
ments for patients treated with monotherapy relative to those 
treated with polypharmacy. Although this comparison was not 
adjusted for background characteristics, it suggests that the 
use of more effective antipsychotic treatments may improve 
the rate of antipsychotic monotherapy. The treatment of 
choice for treatment-resistant schizophrenia, clozapine, was 
not available in Japan until 2009 and therefore could not have 
been used during the study period. The polypharmacy use in 
this study may have been for treatment-resistant patients.
In addition to maximizing the effectiveness of antipsychotic 
treatments for individual patients, other approaches may also 
help to reduce the use of polypharmacy. A recent Japanese study 
found that although poor efficacy was the   primary reason for ini-
tiating antipsychotic polypharmacy, many patients were started 
on polypharmacy prior to maximizing the dose of the initial 
antipsychotic.28 Encouraging physicians in Japan to maximize 
the dose of the initial antipsychotic prior to adding a   second 
medication may help reduce antipsychotic   polypharmacy. 
A randomized study in the US found that many patients 
with schizophrenia could be effectively switched from 
antipsychotic polypharmacy to monotherapy.29 Patients 
who were randomized to switch to monotherapy had similar 
symptom reductions during the 6-month follow-up period as 
those who remained on antipsychotic polypharmacy; however, 
a meaningful proportion (31%) of patients who were switched 
to antipsychotic monotherapy were restarted on polypharmacy 
prior to the end of the study. With the recognition that in certain 
situations antipsychotic polypharmacy may be appropriate,10 
interventions aimed at decreasing polypharmacy in Japan 
may be effective. The results of the current study could be 
used to identify patients who are at increased likelihood of 
  polypharmacy, to more efficiently target interventions.
Limitations
This research was able to identify significant predictors of antip-
sychotic monotherapy. However, the OPMS study included 
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Figure 1 Significant predictors of antipsychotic monotherapy versus polypharmacy in the stepwise logistic regression. 
Notes: Error bars represent the 95% confidence intervals. For the continuous predictors (body mass index [BMI], duration of illness, and age) the odds ratios represent the 
increase in odds of monotherapy for every unit increase in the variable. The confidence intervals for the continuous variables were narrower than the marker.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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only patients with schizophrenia initiated on olanzapine in 
Japan. Although some of the same characteristics have been 
found to be predictive of monotherapy in other geographies, 
the findings may not generalize to other antipsychotics or to 
other countries or geographic regions. Additionally, this study 
defined polypharmacy as 60 or more days of concomitant 
antipsychotic use, whereas other studies have defined polyphar-
macy as any concomitant antipsychotic use. Results may vary 
depending on the definition of antipsychotic polypharmacy that 
was used. Finally, although this study included a large number 
of predictors, there may have been some important predictors 
that were not available in the study dataset.
Conclusion
Consistent with past research, antipsychotic polypharmacy 
was common in the treatment of schizophrenia in Japan. 
  Stepwise logistic regression revealed several significant 
  baseline predictors of later antipsychotic monotherapy 
treatment, including baseline demographics (age, outpatient 
status), clinical status (illness duration, BMI, medical 
  comorbidities), and prior medication use (prior mood 
stabilizer use, prior anticholinergic use, and switching from 
typical or atypical antipsychotics). In general, patients treated 
with monotherapy appeared to have a less complex clinical 
profile. The results of this study could be used to target inter-
ventions aimed at reducing polypharmacy among patients 
who are at an increased risk.
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